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Osteoporosis is a major public health problem becoming
increasingly important as our population ages. Approxi-
mately one in two women will experience an osteoporotic
fracture in their lifetime. Additionally, millions have low
bone mass that increases fracture risk. OBJECTIVE: To
develop a methodology, in a managed care environment,
that identifies members at high-risk for osteoporotic frac-
tures. METHODS: This was a retrospective database
study. The study population was from a Midwest health
plan of 1.38 million lives. The database consisted of all
pharmaceutical, professional, and institutional claims
linked at the patient level. The study population was
identified by the following criteria: continuously enrolled
from 7/1/95 to 3/31/99, complete coverage, individuals
older than age 45 for women and age 65 for men with
fracture of interest, specific fracture by site; hip (820.0 to
821.39), vertebrae (806 to 806.91), and forearm (813.0
to 813.9x), past history of fracture and specific site by V
codes (13.5 and 15.5), chronic users of steroids (180
days exposure over a period of 24 months), history of
transplant (by CPT-4 and V codes), a diagnosis code of
733.0x, current history (in study period) of ICD-9 codes
for pathologic fractures 733.1 to 733.19, a family history
of musculoskeletal disease (V code 17.8), and individuals
with bone density studies (by CPT-4 codes). RESULTS:
Over 120 million claims were screened to stratify the
population (prior to 1997) into risk bands. We used
2,000 patients with current osteoporotic fractures to de-
velop and to verify a predictive model of fracture risk.
CONCLUSIONS: A claims based model identified high-
risk patients for fractures. Application of the model to
1999 data generated a list of patients for intervention.
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Economic models for highly active antiretroviral (HAART)
drug regimens used in HIV infection differ from other
models in that they must accommodate the results of
short trials, but yield relatively long-reaching predictions
of health outcomes, resource use, and costs, in an envi-
ronment where valid epidemiologic data are scarce. Stan-
dard Markov models were effective for short survival
times. With improved treatment options, survival of HIV
patients has been prolonged significantly. A methodolog-
ical consequence is that Markov models with fixed tran-
sition probabilities may no longer be reliable. Further-
more, the number and disparity of outcomes of interest,
such as surrogate marker changes, primary health out-
comes, treatment side effects, degree of adherence, and
viral resistance to subsequent regimens complicate Markov
approaches. OBJECTIVE: To compare two possible so-
lutions:1) a system of linked, staged Markov models; and
2) a hierarchical Monte Carlo simulation. METHODS:
Application of both methods to existing data. FIND-
INGS: The data requirement for the staged Markov sys-
tem depends on whether transitions are derived empiri-
cally or from theory. We found that approximately 27
exposure years are required per health state to ensure sta-
ble incidence densities, and that 12 model states health
states can capture both risk of progression and risk of
events observed in about 1500 patients over 3 years, but
that stable transition rates require at least 50 exposure
years per health state, and vary by antiretroviral experi-
ence. The hierarchical Monte Carlo model has more
modest requirements for data density, but depends on
long streams of uninterrupted observations from unique
patients. The strengths and weaknesses of these two ap-
proaches will be illustrated with data from the ritonavir
and ABT378 trials.
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Within pharmacoeconomic analysis, the generalizability
of results from one jurisdiction to another should not be
presumed. In general re-analysis of data for specific juris-
dictions is required. Thus, the lack of transparency in the
reporting of evaluations can limit their applicability to
decision-making. OBJECTIVES: First, to build a decision
analytic model to replicate the results from a stochastic
analysis of a US trial based economic analysis. Second, to
assess the transferability and generalizability of results to
the Canadian setting. METHODS: A decision analysis
model was developed to replicate results from the US
trial comparing the use of basiliximab and cyclosporin to
placebo and cyclosporin for renal transplant patients. We
determined the necessary parameters required to replicate
the study results and conducted re-analysis for the Cana-
dian setting. Data required related to clinical probabili-
ties, costs of treatments and treatment paths. RESULTS:
Results from the US study were replicated using the deci-
sion analytic model. The cyclosporin-basiliximab arm led
to the least cost path when compared to cyclosporin-pla-
cebo, with costs of $28,858 and $32,253 respectively,
approximating the results of the stochastic analysis of
$28,927 and $32,300. Further analysis was conducted
for the Canadian setting, and found similar results.
CONCLUSIONS: Where the criteria for geographic
transferability are satisfied it is possible to transfer the re-
sults of a clinical trial to other geographic locations.
However, it need not follow that results are generaliz-
able. In addition, when assessing the generalizability of
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results from the published literature, problems arise
where data are incomplete. Thus, more transparent re-
porting of study results are required to aid transferability.
PMT14
IMPROVING THE EVIDENCE BASE OF 
ECONOMIC ANALYSES
Coyle D, Lee KM
Clinical Epidemiology Unit, Loeb Health Research Institute, 
Ottawa Hospital, Ottawa, ON, Canada
OBJECTIVE: To address two specific issues relating to
the conduct of economic analysis based on decision ana-
lytic techniques: the impact on results of different sources
of both effectiveness and resource use data. METHODS:
Sensitivity analysis of erythropoietin use in orthopedic
surgery and alendronate in the treatment of osteoporosis.
Analysis focuses on the effect on the incremental cost-
effectiveness ratio of different sources of treatment effec-
tiveness and resource use. For effectiveness, analysis com-
pared results based on individual clinical trials and meta
analysis. Further analysis compared the results based on
resource use data from the clinical trials and data from
administrative data sets. RESULTS: Results varied greatly
between the different sources of effectiveness and re-
source use data. Based on outcomes from individual clin-
ical trials the cost per QALY gained from alendronate
varied from $27,000 to $104,500. The cost per QALY
gained from a meta analysis of all studies was $35,600.
The cost per life year gained of erythropoietin was more
than ten times greater using actual resource use data in
clinical practice in Ottawa than using trial based data.
CONCLUSIONS: Economic analysis conducted through
decision analytic techniques has been open to criticism
over the ease at which desired results can be obtained. By
adopting standards based on an evidence-based approach
to identifying parameters, such criticisms can be avoided.
Based on the results of this paper we recommend that
meta analysis is the preferred source of outcome data but
routine local data are the best source of resource use data.
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Regression equations from the Framingham Heart Study
(FHS) are used in New Zealand to estimate individual
cardiovascular risk. However, these equations have not
been validated for use in the NZ population. OBJEC-
TIVES: To determine the applicability of FHS regression
equations to the Auckland population, to facilitate eco-
nomic modelling of the management of cardiovascular
risk. METHODS: Population risk profiles for Auckland
were used as inputs to recent FHS equations for CHD
events, stroke and myocardial infarction (MI). Annual
risk was calculated from 5-y risk using a Markov model.
The predictions were compared with 1998-92 MI and
stroke event rates obtained from the MONICA study in
Auckland, and with NZ CHD mortality rates. RE-
SULTS: FHS equations predict the risk of incident MI for
Auckland males age 40–64 within 20%, however they
over-estimate female MI risk by up to 2-fold. The FHS
predicts that CHD event risk stabilises over age 53 for fe-
males although NZ female CHD mortality rates (ICD9
410–414) increase exponentially up to age 80. A FHS
stroke equation fits males 60 years but overestimates
risk for younger men and underestimates stroke risk for
women age 40–74 by 33%. Age-specific relative risk for
females compared with males is consistent across Auck-
land CHD event and mortality data and also NZ CHD
mortality data. CONCLUSIONS: FHS equations with
Auckland risk profile inputs provide a reasonable esti-
mate of population MI risk for Auckland men but not for
women. MI risk for Auckland women can be estimated
from FHS risk for males multiplied by the relative risk
obtained from NZ CHD mortality data. Stroke risk pre-
dicted by the FHS is accurate for NZ men over 60 years
but systematically underestimates risk for NZ women.
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Commercial and private pilots require an annual risk of
an acute incapacitating cardiovascular (CVD) event
1% to maintain their medical certification. OBJEC-
TIVES: (1) to develop a precise, accurate method for esti-
mation of the risk of an acute, incapacitating cardiovas-
cular event, based on a clinical assessment plus blood
lipids, glucose determination and ECG; (2) to determine
the age at threshold for a range of risk profiles. METH-
ODS: Annual risk of CHD, MI and stroke were deter-
mined from recent Framingham regression equations val-
idated for New Zealand. The risk of an acute incapacitating
CHD event is bounded by MI risk and CHD risk. Age at
threshold was estimated from a weighted combination
of Framingham estimates, assuming that 20% of inci-
dent angina pectoris is incapacitating. RESULTS: A non-
diabetic, non-smoking male with age-specific average
Auckland population lipid profile and systolic blood
pressure will reach the 1% per annum threshold for an
incapacitating cardiovascular event at age 60. Males with
30% lower serum cholesterol and 20 points lower sys-
tolic blood pressure will reach the 1% threshold at age
69. Tobacco smoking reduces the age at threshold by 10
years and diabetes by 7 years for males and 12 years for
females. The age at threshold is 12 years higher for
women versus men with similar modifiable risk factors.
A male with several cardiovascular risk factors could
